PRAXIS PRECISION MEDICINES, INC. (PRAX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$96.90M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$105.86M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$78.36M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$76.07M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$96.90M | (m) | (m) | (m) | $245.00K* | -$77.54M* | (m) | $69.42M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$105.86M | (m) | (m) | (m) | $62.00K | -$86.15M | (m) | $77.99M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$78.36M | (m) | (m) | (m) | $0.00* | -$65.06M* | (m) | $65.80M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$76.07M | (m) | (m) | (m) | $56.00K* | -$54.68M* | (m) | $63.01M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$74.73M | (m) | (m) | (m) | $0.00 | -$53.01M | (m) | $60.81M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$56.84M | (m) | (m) | (m) | $0.00* | -$27.50M* | (m) | $41.88M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$37.49M | (m) | (m) | (m) | (m) | -$27.28M* | (m) | $27.26M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$41.89M | (m) | (m) | (m) | (m) | -$20.86M | (m) | $26.98M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$25.52M | (m) | (m) | (m) | $0.00* | -$23.21M* | (m) | $17.26M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$34.96M | (m) | (m) | (m) | $0.00* | -$31.21M* | (m) | $25.61M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$38.09M | (m) | (m) | (m) | $0.00 | -$32.85M | (m) | $25.50M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$44.29M | (m) | (m) | (m) | $45.00K* | -$44.92M* | (m) | $30.44M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$60.39M | (m) | (m) | (m) | $110.00K* | -$57.21M* | (m) | $43.62M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$68.85M | (m) | (m) | (m) | $289.00K | -$54.11M | (m) | $52.65M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$44.77M | (m) | (m) | (m) | $450.00K* | -$23.96M* | (m) | $33.14M | (m) | $5.00K |
| 2021-06-30 | Reported | (m) | -$36.48M | (m) | (m) | (m) | $65.00K* | -$30.01M* | (m) | $25.68M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$27.42M | (m) | (m) | (m) | $4.00K | -$25.72M | (m) | $17.93M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$16.22M | (m) | (m) | (m) | $0.00* | -$13.88M* | (m) | $12.79M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$11.57M | (m) | (m) | (m) | $0.00* | -$9.94M* | (m) | $9.05M | (m) | $3.00K |
| 2020-03-31 | Reported | (m) | -$8.47M | (m) | (m) | (m) | $0.00 | -$8.57M | (m) | $6.87M | (m) | -$11.00K |
| 2019-09-30 | Reported | (m) | -$10.65M | (m) | (m) | (m) | (m) | (m) | (m) | $9.35M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$326.20M | (m) | (m) | (m) | $56.00K | -$249.07M | (m) | $267.12M | (m) | $471.00K |
| 2024-12-31 | Reported | (m) | -$200.16M | (m) | (m) | (m) | $0.00 | -$131.76M | (m) | $152.41M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$126.37M | (m) | (m) | (m) | $50.00K | -$111.14M | (m) | $86.77M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$214.99M | (m) | (m) | (m) | $444.00K | -$185.04M | (m) | $155.04M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$167.33M | (m) | (m) | (m) | $1.05M | -$124.55M | (m) | $120.26M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$61.97M | (m) | (m) | (m) | $0.00 | -$52.62M | (m) | $44.98M | (m) | -$8.00K |
| 2019-12-31 | Reported | (m) | -$35.79M | (m) | (m) | (m) | $103.00K | -$33.42M | (m) | $29.56M | (m) | -$84.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |